178 related articles for article (PubMed ID: 35312718)
1. Disruptions in hepatic glucose metabolism are involved in the diminished efficacy after chronic treatment with glucokinase activator.
Tsumura Y; Tsushima Y; Tamura A; Kato H; Kobayashi T
PLoS One; 2022; 17(3):e0265761. PubMed ID: 35312718
[TBL] [Abstract][Full Text] [Related]
2. TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models.
Tsumura Y; Tsushima Y; Tamura A; Hasebe M; Kanou M; Kato H; Kobayashi T
PLoS One; 2017; 12(2):e0172252. PubMed ID: 28207836
[TBL] [Abstract][Full Text] [Related]
3. The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats.
Erion DM; Lapworth A; Amor PA; Bai G; Vera NB; Clark RW; Yan Q; Zhu Y; Ross TT; Purkal J; Gorgoglione M; Zhang G; Bonato V; Baker L; Barucci N; D'Aquila T; Robertson A; Aiello RJ; Yan J; Trimmer J; Rolph TP; Pfefferkorn JA
PLoS One; 2014; 9(5):e97139. PubMed ID: 24858947
[TBL] [Abstract][Full Text] [Related]
4. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.
De Ceuninck F; Kargar C; Ilic C; Caliez A; Rolin JO; Umbdenstock T; Vinson C; Combettes M; de Fanti B; Harley E; Sadlo M; Lefèvre AL; Broux O; Wierzbicki M; Fourquez JM; Perron-Sierra F; Kotschy A; Ktorza A
Br J Pharmacol; 2013 Jan; 168(2):339-53. PubMed ID: 22925001
[TBL] [Abstract][Full Text] [Related]
5. Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.
Zhang X; Schneck K; Bue-Valleskey J; Yeo KP; Heathman M; Sinha V
J Pharmacokinet Pharmacodyn; 2013 Feb; 40(1):53-65. PubMed ID: 23263772
[TBL] [Abstract][Full Text] [Related]
6. The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection.
Lei L; Liu S; Li Y; Song H; He L; Liu Q; Sun S; Li Y; Feng Z; Shen Z
Eur J Pharmacol; 2018 May; 826():17-23. PubMed ID: 29477658
[TBL] [Abstract][Full Text] [Related]
7. S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.
De Ceuninck F; Kargar C; Charton Y; Goldstein S; Perron-Sierra F; Ilic C; Caliez A; Rolin JO; Sadlo M; Harley E; Vinson C; Ktorza A
Br J Pharmacol; 2013 Jul; 169(5):999-1010. PubMed ID: 23488540
[TBL] [Abstract][Full Text] [Related]
8. Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
Denney WS; Denham DS; Riggs MR; Amin NB
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):517-527. PubMed ID: 27870481
[TBL] [Abstract][Full Text] [Related]
9. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER
Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804
[TBL] [Abstract][Full Text] [Related]
10. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes.
Meininger GE; Scott R; Alba M; Shentu Y; Luo E; Amin H; Davies MJ; Kaufman KD; Goldstein BJ
Diabetes Care; 2011 Dec; 34(12):2560-6. PubMed ID: 21994424
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in glucokinase activators for the treatment of type 2 diabetes.
Pal M
Drug Discov Today; 2009 Aug; 14(15-16):784-92. PubMed ID: 19520181
[TBL] [Abstract][Full Text] [Related]
12. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
[TBL] [Abstract][Full Text] [Related]
13. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
Baker DJ; Wilkinson GP; Atkinson AM; Jones HB; Coghlan M; Charles AD; Leighton B
Br J Pharmacol; 2014 Apr; 171(7):1642-54. PubMed ID: 24772484
[TBL] [Abstract][Full Text] [Related]
14. Clinical investigation of glucokinase activators for the restoration of glucose homeostasis in diabetes.
Li P; Zhu D
J Diabetes; 2024 May; 16(5):e13544. PubMed ID: 38664885
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive review on glucokinase activators: Promising agents for the treatment of Type 2 diabetes.
Thilagavathi R; Hosseini-Zare MS; Malini M; Selvam C
Chem Biol Drug Des; 2022 Feb; 99(2):247-263. PubMed ID: 34714587
[TBL] [Abstract][Full Text] [Related]
16. Lessons from glucokinase activators: the problem of declining efficacy.
Agius L
Expert Opin Ther Pat; 2014 Nov; 24(11):1155-9. PubMed ID: 25266490
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients.
Zhai S; Georgy A; Liang Z; Zhi J
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):552-556. PubMed ID: 27274007
[TBL] [Abstract][Full Text] [Related]
18. Medicine. Drug deals diabetes a one-two punch.
Couzin J
Science; 2003 Jul; 301(5631):290. PubMed ID: 12869732
[No Abstract] [Full Text] [Related]
19. Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus.
Fujieda H; Kogami M; Sakairi M; Kato N; Makino M; Takahashi N; Miyazawa T; Harada S; Yamashita T
Eur J Med Chem; 2018 Aug; 156():269-294. PubMed ID: 30006171
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
